Maintaining Investments in New Innovation Act
Drug Pricing: Delaying Price Negotiations for Gene Therapies
Legislative Progress
Key Points
- This bill changes how long certain high-tech medicines can stay on the market before the government can negotiate lower prices for Medicare. It specifically targets 'advanced drug products' that use gene-targeting technology to treat diseases by changing how genes work.
- Currently, these types of drugs can be chosen for price negotiations after being on the market for 7 years. This bill would push that timeline back to 11 years, giving drug companies an extra four years to sell the medicine at their own chosen price before the government steps in.
- The goal is to encourage companies to keep inventing new treatments for rare or difficult diseases. Supporters believe that because these drugs are very expensive to create, companies need more time to earn back the money they spent on research and development.
- The main trade-off is that Medicare and the people who use it might have to wait longer for lower prices on these specific treatments. Because gene therapies are often among the most expensive medicines available, delaying negotiations could keep government healthcare spending higher for a longer period.
Impact Analysis
Govbase has not yet run an impact analysis on this legislation.
Milestones
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sent to a congressional committee for expert review. The committee decides whether this bill moves forward.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
News
No related news coverage found for this legislation yet.
Source Information
Document Type
Congressional Bill
Official Title
Maintaining Investments in New Innovation Act
Data Sources
Sponsor
Cosponsors
(41)Analysis generated by AI. Always verify with official sources.